Report topline data from the PreciSION CF Phase 2a proof-of-concept trial
Delivered after the deadline (41 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Nov 2025
- Due
- 30 Jun 2026
- Delivered
- 10 Aug 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Topline data from both trials anticipated in mid-2026”
What we found
Evidence strength A What the grades mean
The company reported the topline data on August 10, 2026, which is after the mid-2026 (June 30) deadline.
-
A Sionna Therapeutics, Inc. 8-K filed 2026-08-10
“Sionna Therapeutics, Inc. (Nasdaq: SION)... today reported topline data from two nucleotide binding domain 1 (NBD1) stabilizer programs, the PreciSION CF Phase 2a proof-of-concept (POC) trial” ✓ confirmed on the page
Market reaction: the shares moved -87.7% against the S&P 500 over the three sessions around the disclosure (7 Aug 2026 to 12 Aug 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +84 days
- 2 versions
-
Version 1 · original · stated 5 Nov 2025
Deadline 30 Jun 2026 (“mid-2026”) · wording expected
-
Version 2 · stated 12 May 2026
Deadline 30 Sep 2026 (“summer of 2026”)
“topline data on track for the summer of 2026”
-
Version 3 · stated 6 Aug 2026
Deadline 22 Sep 2026 (“summer of 2026”)
“PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- PreciSION CF Phase 2a trial topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Sionna Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SION-001964 · Corrections policy